Our infographic offers the top takeaways from Congressional Budget Office report that says lower drug prices would decrease industry’s spend on research and development, while rejecting claim that costs of R&D set or impact a particular medicines price.

Upcoming budget proposal likely to include a proposal for funding of a DARPA-like contracting entity. Any focus on innovations and breakthroughs is likely welcome news for industry – though perhaps not the message that government is taking on work that drug companies can’t or won’t do.

Dunn’s participation at the panel meeting ended speculation that he left the US FDA.